The University of Texas M. D. Anderson Cancer Center SPORE in Melanoma

德克萨斯大学 MD 安德森癌症中心 SPORE 黑色素瘤

• 批准号: 8541563
• 负责人: ELIZABETH A GRIMM
• 金额: $ 215.05万
• 依托单位: UNIVERSITY OF TX MD ANDERSON CAN CTR
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-07-09 至 2015-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8541563
• 关键词: Address; Adjuvant Study; Adjuvant Therapy; Angiogenesis Inhibitors; Antibodies; Apoptotic; Autoimmune Process; Back; Binding; Bioinformatics; Biological; Biology; CAP18 lipopolysaccharide-binding protein; Cells; Clinic; Clinical; Clinical Investigator; Clinical Trials; Collaborations; Commit; DNA; Data; Detection; Development; Disease; Dose; Encapsulated; Funding; Gamma Knife Radiosurgery; Genetic; Genetic Polymorphism; Goals; Grant; Health; Immune; Immune response; Immunity; Immunotherapy; Incidence; Inflammation; Inflammatory; Informatics; Institution; Instruction; Interdisciplinary Study; Interferons; Interleukin-2; Intervention; Knowledge; Laboratories; Laboratory Finding; Magnetic Resonance Imaging; Malignant Neoplasms; Melanoma Cell; Metastatic Melanoma; Metastatic Neoplasm to the Central Nervous System; Metastatic malignant neoplasm to brain; Modality; Modeling; Monitor; Neoplasm Metastasis; Oncologist; Operative Surgical Procedures; Outcome; Palliative Care; Pathology; Pathway interactions; Patients; Phase; Population Sciences; Populations at Risk; Pre-Clinical Model; Prevention; Property; Proteins; Protocols documentation; Psoriasis; Radiation; Recurrence; Relapse; Relative (related person); Research; Research Personnel; Research Training; Resistance; Resources; Risk; Role; Scientist; Signal Transduction; Skin; Skin Cancer; Small Interfering RNA; Staging; Stratification; Structure; Surrogate Markers; Systemic Therapy; T-Cell Activation; Technology; Testing; Time; Tissues; Toll-like receptors; Toxic effect; Training Support; Translating; Translational Research; Translations; Treatment Protocols; University of Texas M D Anderson Cancer Center; Validation; base; career development; chemotherapy; design; effective therapy; experience; feeding; gain of function; high risk; human NOS2A protein; immune activation; improved; in vivo; inflammatory marker; inhibitor/antagonist; innovation; knowledge translation; macrophage; melanoma; metastatic process; nanoliposome; nanoparticle; neglect; neoplastic cell; novel; novel strategies; outcome forecast; patient population; population based; pre-clinical; prognostic; programs; response; small molecule; temozolomide; tissue resource; tool; treatment strategy; tumor

DESCRIPTION (provided by applicant): The overall goal of this competing renewal SPORE in skin Cancer from The University of Texas M.D. Anderson Cancer Center is to facilitate innovative translational research in the prevention, detection and treatment of melanoma leading to the elimination of the disease. This SPORE aims to achieve this goal by assembling a talented group of scientists who are committed to the translation of melanoma-specific findings from the laboratory to the clinic as well as from the clinic to the laboratory. The University of Texas M.D. Anderson Cancer Center has prioritized the elimination of melanoma as a health risk, and to this end established in 1998, a Multidisciplinary Research Program in Melanoma to support training and research across traditional administrative boundaries. The program provided resources and a structure that led to our successful funding in 2004 for the first SPORE dedicated entirely to Melanoma, which allowed us to further advance along several translational themes and provide a basis for this renewal application. This SPORE in Melanoma proposes five translational projects, four of which included treatment protocols to begin in successive years and takes advantage of our large melanoma patient population. The five projects and four protocols are served by three cores: Administrative (A), Informatics, Tissue Resource, and Pathology (B), and Biostatics and Bioinformatics (C). The Developmental Research Program (DRP) and Career Development Program (CDP) continue as successful aspects of our SPORE as each new project incorporates at least one DRP/CDP awardee as a new Co-Leader. The five proposed projects address activation of Toll-Like Receptors (TLR) for specific immune stimulation (#1); inhibition of pSTAT3 for control of melanoma metastasis focused in the CNS (#2); elucidation of melanoma JNOS-related inflammation for development of a prognostic signature as well as a target therapy (#3); systemic deliver of angiogenesis inhibitors using nanoliposomal technology (#4); and genetic mechanisms of immunity and inflammation to generate an integrated risk model as part of a population based project (#5). Through this research program and with the full support of The University of Texas M.D. Anderson Cancer Center, this SPORE aims to make a significant impact toward the prevention, detection, and treatment of melanoma in patients.

描述（由申请人提供）：德克萨斯大学医学博士的皮肤癌竞争性更新SPORE的总体目标。安德森癌症中心是促进创新的转化研究，在预防，检测和治疗黑色素瘤，导致消除疾病。这个孢子旨在通过聚集一群有才华的科学家来实现这一目标，他们致力于将黑色素瘤特异性发现从实验室翻译到临床以及从临床到实验室。德克萨斯大学安德森癌症中心已优先消除黑色素瘤作为一种健康风险，并为此在1998年建立了一个黑色素瘤多学科研究计划，以支持跨传统行政边界的培训和研究。该计划提供了资源和结构，使我们在2004年成功资助了第一个完全致力于黑色素瘤的SPORE，这使我们能够进一步推进沿着几个翻译主题，并为这次更新申请提供了基础。黑色素瘤的SPORE提出了五个转化项目，其中四个项目包括连续几年开始的治疗方案，并利用我们庞大的黑色素瘤患者群体。五个项目和四个协议由三个核心服务：行政（A），信息学，组织资源和病理学（B），生物统计学和生物信息学（C）。发展研究计划（DRP）和职业发展计划（CDP）继续作为我们SPORE的成功方面，因为每个新项目都包含至少一名DRP/CDP获奖者作为新的共同领导人。这五个拟议的项目涉及激活Toll样受体（TLR）以进行特异性免疫刺激（#1）;抑制pSTAT 3以控制集中在CNS中的黑色素瘤转移（#2）;阐明黑色素瘤JNOS相关炎症以开发预后特征以及靶向治疗（#3）;使用纳米脂质体技术全身递送血管生成抑制剂（#4）;以及免疫和炎症的遗传机制，以生成综合风险模型，作为基于人群的项目的一部分（#5）。通过这项研究计划，并在德克萨斯大学医学博士的全力支持下，安德森癌症中心，这个孢子的目的是对预防，检测和治疗黑色素瘤的患者产生重大影响。